HighPoint Advisor Group’s Carisma Therapeutics CARM Stock Holding History

HighPoint Advisor Group’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-610	Closed	-$56K	–	571
2021 Q2	$56K	Buy	+610	New	+$38.9K	0.01%	531

Other funds holding CARM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

HighPoint Advisor Group's CARM Position: Q3 2021 in Review

HighPoint Advisor Group sold out of Carisma Therapeutics (CARM) in Q3 2021, closing a stake of 610 shares — an estimated $56K sold.

HighPoint Advisor Group first reported a position in CARM in Q2 2021 and held it in 1 quarter. The position peaked at $56K in Q2 2021. 103 funds tracked by Wall St. Rank hold CARM as of Q3 2021.

HighPoint Advisor Group reported no remaining Carisma Therapeutics position as of Q3 2021 after selling out during the quarter.
HighPoint Advisor Group sold 610 Carisma Therapeutics shares in Q3 2021, an estimated $56K.
HighPoint Advisor Group first reported a position in Carisma Therapeutics in Q2 2021 and held it in 1 quarter.
HighPoint Advisor Group's Carisma Therapeutics position peaked at $56K in Q2 2021.
103 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2021.

Based on HighPoint Advisor Group's 13F filing for Q3 2021, filed 15 Nov 2021.